- Kryxana® / Kisqali® works by blocking the activity of two enzymes (CDK4 and CDK6) that are important for cancer cells growth and division
- Liver function tests (LFTs) should be performed before starting treatment with Kryxana® / Kisqali® and monitored throughout
- Neutropenia (low levels of a type of white blood cells) was the most frequently reported adverse reaction in Kisqali®’s clinical trials
- Patients should be monitored for pulmonary symptoms as severe, life-threatening interstitial lung disease and/or pneumonitis can occur in patients treated with Kryxana® / Kisqali®
- Severe cutaneous reactions have occurred during treatment, discontinue Kryxana® / Kisqali® use if life-threatening reactions are suspected
- Kryxana® / Kisqali® can cause harm to unborn babies, patients should not get pregnant or breast feed while taking it
Please refer to the manufacturer’s website to learn all the information needed to use this medicine safely and effectively
There are no reviews yet.